Neurocrine Biosciences (NBIX) Said Elagolix Endometriosis Phase III On Track After FDA Response to SPA
Go back to Neurocrine Biosciences (NBIX) Said Elagolix Endometriosis Phase III On Track After FDA Response to SPA| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 152.57 -0.36 (0.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $152.93 | 52 Week High | $58.46 | |||
| Open | $153.13 | 52 Week Low | $31.25 | |||
| Day High | $155.27 | P/E | N/A | |||
| Day Low | $152.51 | EPS | $-0.69 | |||
| Volume | 1,227,622 | |||||
